[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019098572A3 - Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus - Google Patents

Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus Download PDF

Info

Publication number
WO2019098572A3
WO2019098572A3 PCT/KR2018/012961 KR2018012961W WO2019098572A3 WO 2019098572 A3 WO2019098572 A3 WO 2019098572A3 KR 2018012961 W KR2018012961 W KR 2018012961W WO 2019098572 A3 WO2019098572 A3 WO 2019098572A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
liver fibrosis
hepatitis virus
fibrosis induced
alleviating liver
Prior art date
Application number
PCT/KR2018/012961
Other languages
French (fr)
Korean (ko)
Other versions
WO2019098572A2 (en
Inventor
김희선
신현주
김창욱
Original Assignee
주식회사 대웅제약
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 대웅제약, 가톨릭대학교 산학협력단 filed Critical 주식회사 대웅제약
Publication of WO2019098572A2 publication Critical patent/WO2019098572A2/en
Publication of WO2019098572A3 publication Critical patent/WO2019098572A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a pharmaceutical composition for alleviating liver fibrosis induced by a hepatitis virus, the composition comprising ursodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
PCT/KR2018/012961 2017-11-15 2018-10-30 Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus WO2019098572A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0152276 2017-11-15
KR1020170152276A KR101887561B1 (en) 2017-11-15 2017-11-15 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis

Publications (2)

Publication Number Publication Date
WO2019098572A2 WO2019098572A2 (en) 2019-05-23
WO2019098572A3 true WO2019098572A3 (en) 2019-07-11

Family

ID=63593798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012961 WO2019098572A2 (en) 2017-11-15 2018-10-30 Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus

Country Status (2)

Country Link
KR (1) KR101887561B1 (en)
WO (1) WO2019098572A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis
KR20240002134A (en) * 2022-06-28 2024-01-04 가톨릭대학교 산학협력단 Composition for preventing, improving or treating nonalcoholic steatohepatitis comprising tenofovir alafenamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120008034A (en) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120008034A (en) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
KR101887561B1 (en) * 2017-11-15 2018-09-06 주식회사 대웅제약 Pharmaceutical composition for improving hepatitis virus-induced liver fibrosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANZAI, TAIKO ET AL.: "Long-tenn combined therapy with very-low-dose peginierferon and ursodeoxycholic acid decreased the spleen size in a patient with hepatitis C virus-related cirrhosis", INTERNAL MEDICINE, vol. 52, no. 3, 2 November 2012 (2012-11-02) - 2013, pages 363 - 367, XP055619001 *
CORPECHOT, CHRISTOPHE ET AL.: "The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliaiy cirrhosis", HEPATOLOGY, vol. 32, no. 6, 2000, pages 1196 - 1199, XP055618978 *
LONG, LI-HUI ET AL.: "Efficacy of hepatoprotective agents with or without antiviral drugs on liver function and fibrosis in patients with hepatitis B: A meta-analysis", HEPATITIS MONTHLY, vol. 15, no. 7, 22 July 2015 (2015-07-22), pages (e29052)1 - (e29052)12, XP055618982 *
TASCI, ILKER ET AL.: "Rat liver fibrosis regresses better with pegylated interferon alpha 2b and ursodeoxycholic acid treatments than spontaneous recovery", LIVER INTERNATIONAL, vol. 26, no. 2, March 2006 (2006-03-01), pages 261 - 268, XP055618991 *

Also Published As

Publication number Publication date
KR101887561B1 (en) 2018-09-06
WO2019098572A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2019014247A8 (en) Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
EP3895717A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
ZA201902051B (en) Pharmaceutical composition
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
EP4041733A4 (en) Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
EP4041734A4 (en) Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
JOP20180071A1 (en) CJ Healthcare Corporation
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MX2020012989A (en) Therapeutic agent for fibrosis.
EP3760195A4 (en) Composition comprisng 2,3-butanediol as active ingredient
WO2019194773A3 (en) The combination comprising linagliptin and metformin
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
WO2019098572A3 (en) Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2021010022A (en) Pharmaceutical composition.
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
WO2016163818A3 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient
MX2016008729A (en) Pharmaceutical composition containing clomipramine and preparation method therefor.
EP3542797A4 (en) Pharmaceutical composition for preventing or treating dyrk-related diseases, containing pyridine-based compound as active ingredient
EP3626703A4 (en) Novel compound and pharmaceutical composition comprising same as active ingredient
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18877363

Country of ref document: EP

Kind code of ref document: A2